ArticleInvestigational new drugs2021

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.

Akihiro Miura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.